4-(tert-Butylsulfanyl)-2,6-di(pyrazol-1-yl)pyridine (L) was obtained in low yield from a one-pot reaction of 2,4,6-trifluoropyridine with 2-methylpropane-2-thiolate and sodium pyrazolate in a 1:1:2 ratio. The materials [FeL ][BF ] ⋅solv (1[BF ] ⋅solv) and [FeL ][ClO ] ⋅solv (1[ClO ] ⋅solv; solv=MeNO , MeCN or Me CO) exhibit a variety of structures and spin-state behaviors including thermal spin-crossover (SCO). Solvent loss on heating 1[BF ] ⋅x MeNO (x≈2.3) occurs in two steps. The intermediate phase exhibits hysteretic SCO around 250 K, involving a "reverse-SCO" step in its warming cycle at a scan rate of 5 K min . The reverse-SCO is not observed in a slower 1 K min measurement, however, confirming its kinetic nature. The final product [FeL ][BF ] ⋅0.75 MeNO was crystallographically characterized, and shows abrupt but incomplete SCO at 172 K which correlates with disorder of an L ligand. The asymmetric unit of 1[BF ] ⋅y Me CO (y≈1.6) contains five unique complex molecules, four of which undergo gradual SCO in at least two discrete steps. Low-spin 1[ClO ] ⋅0.5 Me CO is not isostructural with its BF congener, and undergoes single-crystal-to-single-crystal solvent loss with a tripling of the crystallographic unit cell volume, while retaining the P space group. Three other solvate salts undergo gradual thermal SCO. Two of these are isomorphous at room temperature, but transform to different low-temperature phases when the materials are fully low-spin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/chem.202004072 | DOI Listing |
Dalton Trans
January 2025
State Key Laboratory of Fine Chemicals, Frontier Science Center for Smart Materials, School of Chemical Engineering, Dalian University of Technology, No. 2 Linggong Road, Dalian 116024, P. R. China.
Molecular materials that exhibit synergistic coupling between luminescence and spin-crossover (SCO) behaviors hold significant promise for applications in molecular sensors and memory devices. However, the rational design and underlying coupling mechanisms remain substantial challenges in this field. In this study, we utilized a luminescent complementary ligand pair as an intramolecular luminophore to construct a new Fe-based SCO complex, namely [FeLL](BF)·HO (1-Fe, L is a 2,2':6',2''-terpyridine (TPY) derivative ligand and L is 2,6-di-1-pyrazol-1-yl-4-pyridinecarboxylic acid), and two isomorphic analogs (2-Co, [CoLL](BF)·HO and 3-Zn, [ZnLL](BF)·HO).
View Article and Find Full Text PDFAngew Chem Int Ed Engl
December 2024
School of Chemistry, University of Leeds, Woodhouse Lane, Leeds, UK, LS2 9JT.
Comput Biol Chem
October 2024
College of Chemistry and Life Science, Beijing University of Technology, Beijing 100124, PR China. Electronic address:
Human glutaminyl cyclase (hQC) inhibitors have great potential to be used as anti- Alzheimer's disease (AD) agents by reducing the toxic pyroform of β-amyloid in the brains of AD patients. The four-dimensional quantitative structure activity relationship (4D-QSAR) model of N-substituted urea/thioureas was established with satisfying predictive ability and statistical reliability (Q = 0.521, R = 0.
View Article and Find Full Text PDFInorg Chem
February 2024
School of Chemistry, University of Leeds, Woodhouse Lane, Leeds LS2 9JT, U.K.
Reaction of 2,4,6-trifluoropyridine with sodium 3,4-dimethoxybenzenethiolate and 2 equiv of sodium pyrazolate in tetrahydrofuran at room temperature affords 4-(3,4-dimethoxyphenylsulfanyl)-2,6-di(pyrazol-1-yl)pyridine (), in 30% yield. The iron(II) complexes [Fe][BF] () and [Fe][ClO] () are high-spin with a highly distorted six-coordinate geometry. This structural deviation from ideal symmetry is common in high-spin [Fe(bpp)] (bpp = di{pyrazol-1-yl}pyridine) derivatives, which are important in spin-crossover materials research.
View Article and Find Full Text PDFAnn Rheum Dis
September 2024
MRC Centre for Neuromuscular Diseases, University College London, London, UK.
Objectives: Fatigue is prevalent in people with inflammatory rheumatic and musculoskeletal diseases (I-RMDs) and recognised as one of the most challenging symptoms to manage. The existence of multiple factors associated with driving and maintaining fatigue, and the evidence about what improves fatigue has led to a multifaceted approach to its management. However, there are no recommendations for fatigue management in people with I-RMDs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!